View in EDS

The prevalence of cannabidiol (CBD) use in North America and Europe: A meta‐analysis.

Saved in:
Bibliographic Details
Title: The prevalence of cannabidiol (CBD) use in North America and Europe: A meta‐analysis.
Authors: Weidberg, Sara, Iza‐Fernández, Clara, Alemán‐Moussa, Layla, Krotter, Andrea, González‐Roz, Alba
Source: Addiction. Jul2026, Vol. 121 Issue 7, p1653-1670. 18p.
Subjects: Cannabidiol, Substance abuse, Research funding, Sex distribution, Meta-analysis, Descriptive statistics, Population geography, MEDLINE, Acquisition of data, Sociodemographic factors, Online information services, Confidence intervals, Psychology information storage & retrieval systems, Publication bias
Geographic Terms: Europe, North America
Abstract: Background and aims: The global cannabidiol (CBD) market has expanded in recent years. Several studies suggest CBD use, whether for medical or recreational purposes, is on the rise; however, no systematic assessments of its prevalence have been conducted so far. This meta‐analysis aimed to estimate the prevalence of CBD use in North America and Europe independently. Methods: Searches were conducted in PubMed, PsycINFO and Web of Science on 25 March 2025. A total of 43 studies (48 distinct samples; n = 388 447; 57.52% female) from North America (k = 30; n = 353 088) and Europe (k = 13; n = 35 359) were included in the analyses. The prevalence was estimated at five time periods (i.e. lifetime, past 12 months, past 30 days, past 7 days and daily use) separately for each continent region. Differences in prevalence estimates by sex, year of data collection and sample type (i.e. clinical versus community) were examined. Publication bias was estimated using several indicators, and the methodological quality of the studies was appraised using the Joana Brigg's Institute (JBI) checklist. Results: In preliminary analyses of heterogeneity there was evidence of differences in prevalence between North America and Europe across all time periods (P‐value range: < 0.001–0.057). Consequently, the pooled prevalence estimates were calculated for both continental regions separately. In Europe, the pooled lifetime prevalence of CBD use was 12.8% [95% confidence interval (CI) = 0.06–0.25], 17.6% (95% CI = 0.11–0.28) in the past 12 months, 7.2% (95% CI = 0.02–0.21) in the past month, 4.3% (95% CI = 0.01–0.13) in the past week and 2.1% (95% CI = 0.01–0.08) daily. In North America, lifetime pooled estimates were 28.9% (95% CI = 0.2–0.39), 19.5% in the past 12 months (95% CI = 0.11–0.32), 12% in the past month (95% CI = 0.07–0.2), 10.5% in the past week (95% CI = 0.01–0.47) and 6.4% daily (95% CI = 0.03–0.13). Of the moderators tested, sample type statistically significantly influenced the meta‐analyses. In Europe, clinical samples (25.6%) reported higher past‐year prevalence of CBD use in comparison with community samples (11.6%), whereas in North America there was higher past‐year use of CBD among community samples (26.1%) compared with clinical samples (4.1%). Conclusions: Cannabidiol use appears to be more prevalent in North America compared with Europe. [ABSTRACT FROM AUTHOR]
Copyright of Addiction is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
FullText Text:
  Availability: 0
Header DbId: pbh
DbLabel: Psychology and Behavioral Sciences Collection
An: 194810796
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: The prevalence of cannabidiol (CBD) use in North America and Europe: A meta‐analysis.
– Name: Author
  Label: Authors
  Group: Au
  Data: &lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Weidberg%2C+Sara%22&quot;&gt;Weidberg, Sara&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Iza‐Fern&#225;ndez%2C+Clara%22&quot;&gt;Iza‐Fern&#225;ndez, Clara&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Alem&#225;n‐Moussa%2C+Layla%22&quot;&gt;Alem&#225;n‐Moussa, Layla&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Krotter%2C+Andrea%22&quot;&gt;Krotter, Andrea&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Gonz&#225;lez‐Roz%2C+Alba%22&quot;&gt;Gonz&#225;lez‐Roz, Alba&lt;/searchLink&gt;
– Name: TitleSource
  Label: Source
  Group: Src
  Data: &lt;searchLink fieldCode=&quot;JN&quot; term=&quot;%22Addiction%22&quot;&gt;Addiction&lt;/searchLink&gt;. Jul2026, Vol. 121 Issue 7, p1653-1670. 18p.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: &lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Cannabidiol%22&quot;&gt;Cannabidiol&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Substance+abuse%22&quot;&gt;Substance abuse&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Research+funding%22&quot;&gt;Research funding&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Sex+distribution%22&quot;&gt;Sex distribution&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Meta-analysis%22&quot;&gt;Meta-analysis&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Descriptive+statistics%22&quot;&gt;Descriptive statistics&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Population+geography%22&quot;&gt;Population geography&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22MEDLINE%22&quot;&gt;MEDLINE&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Acquisition+of+data%22&quot;&gt;Acquisition of data&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Sociodemographic+factors%22&quot;&gt;Sociodemographic factors&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Online+information+services%22&quot;&gt;Online information services&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Confidence+intervals%22&quot;&gt;Confidence intervals&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Psychology+information+storage+%26+retrieval+systems%22&quot;&gt;Psychology information storage &amp; retrieval systems&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Publication+bias%22&quot;&gt;Publication bias&lt;/searchLink&gt;
– Name: SubjectGeographic
  Label: Geographic Terms
  Group: Su
  Data: &lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Europe%22&quot;&gt;Europe&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22North+America%22&quot;&gt;North America&lt;/searchLink&gt;
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: Background and aims: The global cannabidiol (CBD) market has expanded in recent years. Several studies suggest CBD use, whether for medical or recreational purposes, is on the rise; however, no systematic assessments of its prevalence have been conducted so far. This meta‐analysis aimed to estimate the prevalence of CBD use in North America and Europe independently. Methods: Searches were conducted in PubMed, PsycINFO and Web of Science on 25 March 2025. A total of 43 studies (48 distinct samples; n = 388 447; 57.52% female) from North America (k = 30; n = 353 088) and Europe (k = 13; n = 35 359) were included in the analyses. The prevalence was estimated at five time periods (i.e. lifetime, past 12 months, past 30 days, past 7 days and daily use) separately for each continent region. Differences in prevalence estimates by sex, year of data collection and sample type (i.e. clinical versus community) were examined. Publication bias was estimated using several indicators, and the methodological quality of the studies was appraised using the Joana Brigg&#39;s Institute (JBI) checklist. Results: In preliminary analyses of heterogeneity there was evidence of differences in prevalence between North America and Europe across all time periods (P‐value range: &lt; 0.001–0.057). Consequently, the pooled prevalence estimates were calculated for both continental regions separately. In Europe, the pooled lifetime prevalence of CBD use was 12.8% [95% confidence interval (CI) = 0.06–0.25], 17.6% (95% CI = 0.11–0.28) in the past 12 months, 7.2% (95% CI = 0.02–0.21) in the past month, 4.3% (95% CI = 0.01–0.13) in the past week and 2.1% (95% CI = 0.01–0.08) daily. In North America, lifetime pooled estimates were 28.9% (95% CI = 0.2–0.39), 19.5% in the past 12 months (95% CI = 0.11–0.32), 12% in the past month (95% CI = 0.07–0.2), 10.5% in the past week (95% CI = 0.01–0.47) and 6.4% daily (95% CI = 0.03–0.13). Of the moderators tested, sample type statistically significantly influenced the meta‐analyses. In Europe, clinical samples (25.6%) reported higher past‐year prevalence of CBD use in comparison with community samples (11.6%), whereas in North America there was higher past‐year use of CBD among community samples (26.1%) compared with clinical samples (4.1%). Conclusions: Cannabidiol use appears to be more prevalent in North America compared with Europe. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: &lt;i&gt;Copyright of Addiction is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder&#39;s express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.&lt;/i&gt; (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=194810796
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1111/add.70360
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 18
        StartPage: 1653
    Subjects:
      – SubjectFull: Cannabidiol
        Type: general
      – SubjectFull: Substance abuse
        Type: general
      – SubjectFull: Research funding
        Type: general
      – SubjectFull: Sex distribution
        Type: general
      – SubjectFull: Meta-analysis
        Type: general
      – SubjectFull: Descriptive statistics
        Type: general
      – SubjectFull: Population geography
        Type: general
      – SubjectFull: MEDLINE
        Type: general
      – SubjectFull: Acquisition of data
        Type: general
      – SubjectFull: Sociodemographic factors
        Type: general
      – SubjectFull: Online information services
        Type: general
      – SubjectFull: Confidence intervals
        Type: general
      – SubjectFull: Psychology information storage & retrieval systems
        Type: general
      – SubjectFull: Publication bias
        Type: general
      – SubjectFull: Europe
        Type: general
      – SubjectFull: North America
        Type: general
    Titles:
      – TitleFull: The prevalence of cannabidiol (CBD) use in North America and Europe: A meta‐analysis.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Weidberg, Sara
      – PersonEntity:
          Name:
            NameFull: Iza‐Fernández, Clara
      – PersonEntity:
          Name:
            NameFull: Alemán‐Moussa, Layla
      – PersonEntity:
          Name:
            NameFull: Krotter, Andrea
      – PersonEntity:
          Name:
            NameFull: González‐Roz, Alba
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 07
              Text: Jul2026
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-print
              Value: 09652140
          Numbering:
            – Type: volume
              Value: 121
            – Type: issue
              Value: 7
          Titles:
            – TitleFull: Addiction
              Type: main
ResultId 1